Former OpenAI science lead Kevin Weil has launched Warp Sciences, a new artificial intelligence startup focused on automating lab work for drug discovery, TechCrunch reported on October 22. The company has raised $215 million at an $865 million valuation, according to Weil, who announced the startup and the funding on X.

The round was led by Lightspeed, with participation from IVP, Mayfield, Lux Capital, Premji Invest and Menlo Ventures.

Warp Sciences trains robots to make and test promising compounds identified by researchers. Its human chemists wear cameras and sensor gloves so the robots can learn lab tasks from real technique, with the aim of running wet-lab work around the clock.

For years, biotech companies have outsourced the most labour-intensive synthesis work — making thousands of variations of molecules — to contractors in China such as WuXi AppTec. Weil hopes to reshore that work and insulate the drug development process from geopolitical supply-chain risks.